(Total Views: 558)
Posted On: 12/02/2024 8:59:35 AM
Post# of 148854
While bevacizumab might help extend overall survival by a few months, the quality of life is not improved much. Bevacizumab (Avastin) has a horrible safety profile. Because many of the trials, Avastin was used in, were too small to power statistical significance, here is a paper that pooled several trials to show that it had statistical significance in OAS and PFS. This paper is from 2013.
https://pmchttps.ncbi.nlm.nih.gov/articles/PMC3780632/
The analysis population comprised 3,763 patients (1,773 chemotherapy with or without placebo; 1,990 chemotherapy plus bevacizumab). The addition of bevacizumab to chemotherapy was associated with statistically significant increases in overall survival (OS; HR, 0.80; 95% CI, 0.71–0.90) and progression-free survival (PFS; HR, 0.57; 95% CI, 0.46–0.71). The effects on OS and PFS across subgroups defined by chemotherapy backbone (oxaliplatin-based, irinotecan-based), extent of disease (liver metastases only, extensive disease), age (<65, ≥65 years), Eastern Cooperative Oncology Group performance status (0, ≥1), and KRAS status (wild-type, mutant) were consistent with the overall analysis. Incidence rates of grade ≥3 hypertension, proteinuria, bleeding, wound-healing complications, gastrointestinal perforations, and thromboembolic events were increased with bevacizumab treatment.
Leronlimab should improve the patient's quality of life and extend their OAS and PFS much better than Avastin. I wonder if the down-regulation of VEGF, from Leronlimab, can be measured against what bevacizumab does? If I had the death sentence of mCRC, I would not want Avastin (bevacizumab) as part of my treatment. It just looks like a horrible way to die!
https://pmchttps.ncbi.nlm.nih.gov/articles/PMC3780632/
The analysis population comprised 3,763 patients (1,773 chemotherapy with or without placebo; 1,990 chemotherapy plus bevacizumab). The addition of bevacizumab to chemotherapy was associated with statistically significant increases in overall survival (OS; HR, 0.80; 95% CI, 0.71–0.90) and progression-free survival (PFS; HR, 0.57; 95% CI, 0.46–0.71). The effects on OS and PFS across subgroups defined by chemotherapy backbone (oxaliplatin-based, irinotecan-based), extent of disease (liver metastases only, extensive disease), age (<65, ≥65 years), Eastern Cooperative Oncology Group performance status (0, ≥1), and KRAS status (wild-type, mutant) were consistent with the overall analysis. Incidence rates of grade ≥3 hypertension, proteinuria, bleeding, wound-healing complications, gastrointestinal perforations, and thromboembolic events were increased with bevacizumab treatment.
Leronlimab should improve the patient's quality of life and extend their OAS and PFS much better than Avastin. I wonder if the down-regulation of VEGF, from Leronlimab, can be measured against what bevacizumab does? If I had the death sentence of mCRC, I would not want Avastin (bevacizumab) as part of my treatment. It just looks like a horrible way to die!
(12)
(0)Scroll down for more posts ▼
